Status:
NOT_YET_RECRUITING
Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study
Lead Sponsor:
Institut Curie
Conditions:
Uveal Melanoma
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this prospective observational study is to learn about patient quality of life and experience and medical information needs during uveal melanoma post-treatment surveillance. Participants ...
Detailed Description
Context and scientific background Uveal melanoma (UM) is the most common malignant ocular tumour in adults. It is a rare disease with an incidence of four to seven new cases per million per year in we...
Eligibility Criteria
Inclusion
- Patient aged 18 years or older.
- Diagnosed with a non-metastatic uveal melanoma
- Completion of primary tumour treatment ≥ 6 months (+/- two months).
- Able to respect scheduled visits.
- Able to read and understand the language of the questionnaires.
- Two groups of patients will be identified:
- Patients with non-metastatic uveal melanoma at high risk for metastatic relapse defined as:
- T2b/c/d or ≥ T3,
- or anomaly on either chromosome 3 or chromosome 8, found by CGH array or sequencing.
- Patients with non-metastatic uveal melanoma at low risk of recurrence defined as:
- T2a,
- and/or no alteration of chromosome 3 or chromosome 8 has been found.
Exclusion
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06073548
Start Date
October 1 2023
End Date
April 1 2026
Last Update
October 10 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.